Overview
Inhibits PDE4 and PDE3, reduces TNF-α and leukotriene B4 in mucosal tissue.
Proposed mechanism
Amlexanox is a small-molecule peptide analog that inhibits phosphodiesterase and leukotriene synthesis, reducing mucosal inflammation and pain.
What the evidence supports
Human data exists but the trials are small, short-term, or not yet replicated.
Graded Human-limited
Human data that exists but is thin: open-label work, single-arm studies, small cohorts, or observational follow-up without randomisation.
Key citations
Representative primary sources, including results that did not favour the compound.
- [1]
Amlexanox for aphthous ulcers
· DOI:10.1177/1060028010361922 · 2010
- [2]
Topical amlexanox review
· DOI:10.2147/DDDT.S72682 · 2015
- [3]
Amlexanox for aphthous ulcers (2010)
· · 0
- [4]
Topical amlexanox review (2015)
· · 0
Citation records in this build are illustrative placeholders for the design.
Reference information for research purposes. Not medical advice, and not a recommendation to use any compound. Many entries describe substances that are not approved for human use.